Tech Company Financing Transactions
EpilepsyGTx Funding Round
On 12/10/2025, EpilepsyGTx raised $33 million in Series A investment from British Business Bank, private investors and XGen Ventures.
Transaction Overview
Company Name
Announced On
12/10/2025
Transaction Type
Venture Equity
Amount
$33,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance its lead programme EPY201 through Phase 1/2a clinical trials. The funding will enable the delivery of first-in-human Phase 1/2a clinical trials to establish the safety and efficacy of the company's lead gene therapy programme EPY201 in a broad population of patients with focal refractory epilepsy (FRE).
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Building 1000 Cambridge Research Park Beach Drive
Waterbeach Cambridgeshire, CB25 9PD
UK
Waterbeach Cambridgeshire, CB25 9PD
UK
Phone
Website
Email Address
Overview
EpilepsyGTx is a late preclinical-stage biotech developing cutting-edge gene therapies that will transform the management of focal refractory epilepsy (FRE). Focal epilepsy describes a group of disorders in which patients experience seizures that arise from a specific part of the brain1. Refractory epilepsy occurs when seizures persist despite trials of at least two tolerated and appropriately chosen antiseizure medicines2.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 12/10/2025: Bioxodes venture capital transaction
Next: 12/11/2025: Subsense venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








